AKBAAkebia Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $236M
- 47% YoY
- Operating margin
- 9.9%
- 132% YoY
- EBITDA
- $25M
- 151% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -4.3×
- −$106M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear17% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $212M | $292M | $195M | $160M | $236M | 47% |
| Operating income | −$265M | −$81M | −$46M | −$50M | $23M | 147% |
| Net income | −$282M | −$94M | −$52M | −$69M | −$5M | 92% |
| Operating cash flow | −$253M | −$73M | −$23M | −$41M | $68M | 267% |
| Capex | $59K | $114K | $0 | $33K | $291K | 782% |
| Stock-based comp | $23M | $18M | $9M | $8M | $11M | 45% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $6M | $4M | 58 | 125 |
| FY2024 | $4M | $6M | 68 | 93 |
| FY2023 | $3M | $5M | 44 | 94 |
| FY2022 | $3M | $708K | 21 | 90 |
| FY2021 | $3M | $2M | 81 | 100 |